RhumbLine Advisers
IRD

RhumbLine Advisers’s Opus Genetics IRD Stock Holding History

RhumbLine Advisers’s Portfolio IRD Stock Details IRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$212K Buy
+51,464
New +$240K ﹤0.01% 3257
2024
Q3 		– Sell
-26
Closed -$39 – 4350
2024
Q2 		$39 Sell
26
-3
-10% -$5 ﹤0.01% 4353
2024
Q1 		$58 Hold
29
– – ﹤0.01% 4235
2023
Q4 		$87 Hold
29
– – ﹤0.01% 4250
2023
Q3 		$97 Hold
29
– – ﹤0.01% 4282
2023
Q2 		$125 Buy
+29
New +$138 ﹤0.01% 4365

Other funds holding IRD

CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

RhumbLine Advisers's IRD Position: Q2 2026 in Review

RhumbLine Advisers opened a new position in Opus Genetics (IRD) in Q2 2026: 51,464 shares worth $212K. The stake represents ﹤0.01% of the portfolio and ranks #3257 among its holdings. This is a return to the name: RhumbLine Advisers previously reported a position in IRD as recently as Q2 2024.

RhumbLine Advisers first reported a position in IRD in Q2 2023 and has held it in 6 quarters since. 103 funds tracked by Wall St. Rank hold IRD as of Q2 2026.

  • RhumbLine Advisers held 51,464 shares of Opus Genetics worth $212K as of Q2 2026.
  • Opus Genetics was a new RhumbLine Advisers position in Q2 2026.
  • Opus Genetics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #3257 holding.
  • RhumbLine Advisers first reported a position in Opus Genetics in Q2 2023 and has held it in 6 quarters since.
  • 103 funds tracked by Wall St. Rank held Opus Genetics as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.